AmideBio LLC Competitors

Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia is using its proprietary oral antibody platform to develop gut-targeted therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.

A biotechnology company developing novel medicines with immune regulating technology. We are focusing on therapeutics of.

Ember Therapeutics is a product-focused company translating its world-class biology in the emerging area of brown fat and recent breakthroughs in understanding the mechanisms of selective insulin sensitivity into a proprietary pipeline of peripherally-acting treatments for metabolic disease, including Type 2 diabetes and obesity.